Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 2.13 Billion |
| USD 2.96 Billion | |
| % | |
|
Global Haematology Market, By Product (Haematology Analyzers, Flow Cytometers, Coagulation Analyzers, Slide Stainers, Centrifuges, Hemoglobinometers, and Others), Reagent (Coagulation Reagents, Flow Cytometry Reagents, Immuno-Haematology Reagents, and Others), Application (Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease, and Others), End User (Hospitals, Clinical Testing Institutes, Patient Self-testing, and Other) – Industry Trends and Forecast to 2029
The market for haematology is likely to be driven by the rates for automated haematology instruments and the preferences for high-sensitivity point-of-care (POC) haematology tests. Rapid technology advancements, such as applying fundamental flow cytometry techniques and expanding high throughput haematology analyzers, are also projected to significantly impact the industry's drivers.
Data Bridge Market Research analyses that the haematology market which was USD 2.13 billion in 2021, would rocket up to USD 2.96 billion by 2029, and is expected to undergo a CAGR of 4.20% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Haematology Analyzers, Flow Cytometers, Coagulation Analyzers, Slide Stainers, Centrifuges, Hemoglobinometers, and Others), Reagent (Coagulation Reagents, Flow Cytometery Reagents, Immuno-Haematology Reagents, and Others), Application (Drug Testing, Auto Immune Disease, Cancer, Diabetes Mellitus, Infectious Disease, and Others), End User (Hospitals, Clinical Testing Institutes, Patient Self-testing, and Other)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Siemens (Germany), Abbott (U.S.), Erba Mannheim (Germany), Abaxis (U.S.), Heska Corporation (U.S.), Sysmex Corporation (Japan), Danaher (U.S.), Nihon Kohden Corporation (Japan), Siemens (Germany), Abbott (U.S.), Boule Diagnostics (Sweden), HORIBA (Japan), Bio-Rad Laboratories Inc. (U.S.), BioSystems (U.S.), Diatron (Hungary), Drew Scientific (U.S.), EKF Diagnostics (U.K.), Mindray Medical India Pvt. Ltd. (China), Ortho Clinical Diagnostics (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Hematology analyzers are medical instruments that are used to classify and count the number of blood cells in a patient's blood sample. Differential white blood cell counts are also analyzed using these equipment. The features of haematology analyzers vary according to the different medical equipment, and users can specify which testing service or analysis they require depending on these features.
Drivers
The rise in blood disorders and other diseases, the quick development of haematology technology, and the appearance of high throughput haematology analyzers are all factors in the expansion of the haematology market. One of the key factors influencing the market is the rising incidence of chronic blood illnesses, which is anticipated to increase demand for haematology analyzers.
Another significant factor influencing the growth rate of the haematology market is the rising healthcare expenditure which helps improve its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding, which will further influence the market dynamics.
Opportunities
Furthermore, growing R&D initiatives demonstrating the efficacies of haematology analyzers are anticipated to benefit market expansion. For instance, automated hematologic analyzers are frequently employed in medical laboratories, according to a paper published in February 2021 titled "Establishment of enhanced review criteria for haematology analyzers in cancer institutions." The haematology analyzers market segment for cell surface markers detection will grow as a result of the hospital environment.
Restraints/Challenges
On the other hand, the huge expense of haematology analyzers, merchandise summons, and the sluggish enactment of unconventional haematology devices in developing nations will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the haematology market.
Product recalls slow technology adoption and regulatory and reimbursement concerns are going to restrain the market in the forecast period.
This haematology market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the haematology market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
The market has been slightly damaged by the COVID-19 pandemic. In order to measure COVID-19, haematological criteria are being stressed more widely. Using instruments like haematological analyzers, many hospitals have tested and kept track of COVID-19 patients. Important prognostic indicators such as lymphopenia, neutrophilia, leukocytosis, and thrombocytopenia—all of which are common findings in SARS-CoV-2 virus patients—can only be provided by a clinical haematology laboratory. Furthermore, hospitalization, pneumonia, and pain were more likely among COVID-19 and sickle cell disease (SCD) patients. SCD patients needed to have their health closely monitored since they were more prone to contract new infections. This had a big effect on the market.
Recent Development
The haematology market is segmented on the basis of product, reagent, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
Reagent
Application
End User
The haematology market is analyzed and market size insights and trends are provided by country, product, reagent, application and end user as referenced above.
The countries covered in the haematology market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the haematology market due to the growing geriatric population and innovative medical technology adoption.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the rising health awareness among the people and the growing demand of advanced medical technology.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
The haematology market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to haematology market.
Some of the major players operating in the haematology market are:
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL HAEMATOLOGY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL HAEMATOLOGY MARKET
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET GUIDE
2.2.4 COMPANY POSITIONING GRID
2.2.5 COMAPANY MARKET SHARE ANALYSIS
2.2.6 MULTIVARIATE MODELLING
2.2.7 TOP TO BOTTOM ANALYSIS
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 SALES VOLUME
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARMY DATABASES
2.3 GLOBAL HAEMATOLOGY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 REGULATORY SCENARIO
6 PREMIUM INSIGHTS
6.1 EXISTING LEGAL FRAMEWORK FOR GLOBAL HAEMATOLOGY MARKET
6.1.1 INTERNATIONAL STANDARDS
6.1.2 REGIONAL STANDARDS
6.1.3 VIEWPOINTS OF KEY OPINION LEADERS
6.1.4 MARKET VIEWPOINT OF KEY OPINION LEADERS
6.1.5 EXPERT OPINION SURVEY
6.1.6 EXPECTATION OF FUTURE MARKET SCENARIOS
6.1.7 FINDINGS AND REGIONAL TRENDS
7 GLOBAL HAEMATOLOGY MARKET, BY PRODUCT AND SERVICES
(NOTE: MARKET VALUE,(USD MILLION), VOLUME(UNIT) AND ASP(USD) WILL BE PROVIDED FOR EACH OF THE SEGMENT)
7.1 OVERVIEW
7.2 PRODUCTS
7.2.1 INSTRUMENTS
7.2.1.1. HAEMATOLOGY ANALYZERS
7.2.1.1.1. BY TYPE
7.2.1.1.1.1 AUTOMATED
7.2.1.1.1.2 MANUAL
7.2.1.1.2. BY NUMBER OF PART
7.2.1.1.2.1 3-PART
7.2.1.1.2.2 5-PART
7.2.1.1.2.3 OTHERS
7.2.1.1.3. BY PRICE
7.2.1.1.3.1 HIGH RANGE
7.2.1.1.3.2 LOW RANGE
7.2.1.1.3.3 MID RANGE
7.2.1.2. HAEMATOLOGY CELL COUNTERS
7.2.1.2.1. BY CONFIGURATION
7.2.1.2.1.1 PORTABLE
7.2.1.2.1.2 BENCHTOP
7.2.1.2.2. BY TYPE
7.2.1.2.2.1 AUTOMATED
7.2.1.2.2.2 SEMI-AUTOMATED
7.2.1.3. COAGULATION ANALYZERS
7.2.1.3.1. BY TECHNOLOGY
7.2.1.3.1.1 MECHANICAL
7.2.1.3.1.2 ELECTROCHEMICAL
7.2.1.3.1.3 OPTICAL
7.2.1.3.1.4 OTHERS
7.2.1.4. BY TEST TYPE
7.2.1.4.1. PT (PROTHROMBIN TIME TEST)
7.2.1.4.2. APTT (ACTIVATED PARTIAL THROMBOPLASTIN TIME)
7.2.1.4.3. FIBRINOGEN
7.2.1.4.4. OTHERS
7.2.1.5. BY SAMPLE TYPE
7.2.1.5.1. BLOOD
7.2.1.5.2. PLASMA
7.2.1.5.3. SERUM
7.2.1.6. BY TYPE
7.2.1.6.1. SEMI-AUTOMATED
7.2.1.6.2. FULLY-AUTOMATED
7.2.1.7. BY CONFIGURATION
7.2.1.7.1. BENCHTOP
7.2.1.7.2. PORTABLE
7.2.1.8. BY CHANNELS
7.2.1.8.1. 1 CHANNEL
7.2.1.8.2. 2 CHANNELS
7.2.1.8.3. 3 CHANNELS
7.2.1.8.4. OTHERS
7.2.1.9. FLOW CYTOMETERS
7.2.1.9.1. CELL-BASED
7.2.1.9.1.1 HIGH RANGE
7.2.1.9.1.2 LOW RANGE
7.2.1.9.1.3 MID RANGE
7.2.1.10. BEAD-BASED
7.2.1.10.1. HIGH RANGE
7.2.1.10.2. LOW RANGE
7.2.1.10.3. MID RANGE
7.2.2 SLIDE STAINERS
7.2.2.1. AUTOMATED
7.2.2.2. MANUAL
7.2.3 CENTRIFUGES
7.2.3.1. BY TYPE
7.2.3.1.1. MULTIPURPOSE CENTRIFUGES
7.2.3.1.2. MICROCENTRIFUGES
7.2.3.1.3. ULTRACENTRIFUGES
7.2.3.1.4. MINICENTRIFUGES
7.2.3.2. BY ROTOR TYPE
7.2.3.2.1. FIXED ANGLE
7.2.3.2.2. HORIZONTAL
7.2.3.2.3. OTHERS
7.2.3.3. BY OPERATION
7.2.3.3.1. AUTOMATIC
7.2.3.3.2. SEM IAUTOMATIC
7.2.3.3.3. MANUAL
7.2.3.4. BY MODALITY
7.2.3.4.1. BENCHTOP
7.2.3.4.2. STANDALONE
7.2.4 HEMOGLOBINOMETERS
7.2.4.1. BY MODALITY
7.2.4.1.1. BENCHTOP
7.2.4.1.2. PORTABLE
7.2.4.2. BY TYPE
7.2.4.2.1. FULLY-AUTOMATED
7.2.4.2.2. SEMI-AUTOMATED
7.2.5 HAEMATOLOGY INCUBATOR
7.2.5.1. BY MODALITY
7.2.5.1.1. BENCHTOP
7.2.5.1.2. PORTABLE
7.2.5.1.3. STANDALONE
7.2.5.2. BY TYPE
7.2.5.2.1. FULLY-AUTOMATED
7.2.5.2.2. SEMI-AUTOMATED
7.2.5.3. BY NUMBER OF DOORS
7.2.5.3.1. 1 DOOR
7.2.5.3.2. 2 DOOR
7.2.5.4. BY STERILIZATION CHAMBER MATERIAL
7.2.5.4.1. STAINLESS STEEL
7.2.5.4.2. ALUMINIUM
7.2.6 HEMATOLOGY SAMPLE PREPARATION SYSTEMS
7.2.6.1. BY MODALITY
7.2.6.1.1. BENCHTOP
7.2.6.1.2. PORTABLE
7.2.6.1.3. STANDALONE
7.2.6.2. BY TYPE
7.2.6.2.1. FULLY-AUTOMATED
7.2.6.2.2. SEMI-AUTOMATED
7.2.6.2.3. OTHERS
7.2.7 REAGENTS
7.2.7.1. COAGULATION REAGENTS
7.2.7.2. FLOW CYTOMETRY REAGENTS
7.2.7.3. IMMUNO-HAEMATOLOGY REAGENTS
7.2.7.4. OTHERS
7.2.8 TEST KITS
7.2.8.1. SELF TEST
7.2.8.2. DIGITAL TEST
7.2.8.3. RAPID TESTS
7.2.9 STRIPS
7.2.10 CASSETTE
7.2.11 STANDARD AND CONTROLS
7.2.12 OTHERS
7.3 SERVICES
7.3.1 POINT OF CARE TESTING SERVICES
7.3.2 RAPID TESTING SERVICES
7.3.3 CONVENTIONAL TESTING SERVICES
8 GLOBAL HAEMATOLOGY MARKET, BY DEMOGRAPHY
8.1 OVERVIEW
8.2 HUMAN
8.3 VETERINARY
9 GLOBAL HAEMATOLOGY MARKET, BY TYPE
9.1 OVERVIEW
9.2 FULLY-AUTOMATED
9.3 SEMI-AUTOMATED
9.4 MANUAL
10 GLOBAL HAEMATOLOGY MARKET, BY MODALITY
10.1 OVERVIEW
10.2 BENCHTOP
10.3 STANDALONE
10.4 PORTABLE
10.5 OTHERS
11 GLOBAL HAEMATOLOGY MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 CANCER
11.2.1 PRODUCT
11.2.2 SERVICES
11.2.3 POINT OF CARE TESTING SERVICES
11.2.4 RAPID TESTING SERVICES
11.2.5 CONVENTIONAL TESTING SERVICES
11.3 INFECTIOUS DISEASE
11.3.1 PRODUCT
11.3.2 SERVICES
11.3.3 POINT OF CARE TESTING SERVICES
11.3.4 RAPID TESTING SERVICES
11.3.5 CONVENTIONAL TESTING SERVICES
11.4 DRUG TESTING
11.4.1 PRODUCT
11.4.2 SERVICES
11.4.3 POINT OF CARE TESTING SERVICES
11.4.4 RAPID TESTING SERVICES
11.4.5 CONVENTIONAL TESTING SERVICES
11.5 AUTO IMMUNE DISEASE
11.5.1 PRODUCT
11.5.2 SERVICES
11.5.3 POINT OF CARE TESTING SERVICES
11.5.4 RAPID TESTING SERVICES
11.5.5 CONVENTIONAL TESTING SERVICES
11.6 DIABETES
11.6.1 PRODUCT
11.6.2 SERVICES
11.6.3 POINT OF CARE TESTING SERVICES
11.6.4 RAPID TESTING SERVICES
11.6.5 CONVENTIONAL TESTING SERVICES
11.7 HEMOPHILIA
11.7.1 PRODUCT
11.7.2 SERVICES
11.7.3 POINT OF CARE TESTING SERVICES
11.7.4 RAPID TESTING SERVICES
11.7.5 CONVENTIONAL TESTING SERVICES
11.8 THROMBOSIS
11.8.1 PRODUCT
11.8.2 SERVICES
11.8.3 POINT OF CARE TESTING SERVICES
11.8.4 RAPID TESTING SERVICES
11.8.5 CONVENTIONAL TESTING SERVICES
11.9 BLOOD SCREENING
11.9.1 PRODUCT
11.9.2 SERVICES
11.9.3 POINT OF CARE TESTING SERVICES
11.9.4 RAPID TESTING SERVICES
11.9.5 CONVENTIONAL TESTING SERVICES
11.1 OTHERS
12 GLOBAL HAEMATOLOGY MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.2.1 BY TIER
12.2.2 TIER 1
12.2.3 TIER 2
12.2.4 TIER 3
12.2.5 BY TYPE
12.2.6 PUBLIC
12.2.7 PRIVATE
12.3 CLINICS
12.4 DIAGNOSTIC LABORATORIES
12.5 PATHOLOGY
12.6 RESEARCH AND DEVELOPMENT CENTERS
12.7 OTHERS
13 GLOBAL HAEMATOLOGY MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDERS
13.3 RETAIL SALES
13.4 OTHERS
14 GLOBAL HAEMATOLOGY MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14.5 MERGERS & ACQUISITIONS
14.6 NEW PRODUCT DEVELOPMENT & APPROVALS
14.7 EXPANSIONS
14.8 REGULATORY CHANGES
14.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
14.1 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
15 GLOBAL HAEMATOLOGY MARKET, SWOT AND DBMR ANALYSIS
16 GLOBAL HAEMATOLOGY MARKET, BY COUNTRY
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 U.K.
16.2.3 FRANCE
16.2.4 ITALY
16.2.5 SPAIN
16.2.6 NETHERLANDS
16.2.7 SWITZERLAND
16.2.8 RUSSIA
16.2.9 BELGIUM
16.2.10 TURKEY
16.2.11 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 CHINA
16.3.2 JAPAN
16.3.3 INDIA
16.3.4 SOUTH KOREA
16.3.5 SINGAPORE
16.3.6 THAILAND
16.3.7 MALAYSIA
16.3.8 AUSTRALIA
16.3.9 VIETNAM
16.3.10 REST OF ASIA-PACIFIC
16.4 SOUTH AMERICA
16.4.1 BRAZIL
16.4.2 ARGENTINA
16.4.3 REST OF SOUTH AMERICA
16.5 MIDDLE EAST AND AFRICA
16.5.1 SOUTH AFRICA
16.5.2 SAUDI ARABIA
16.5.3 UAE
16.5.4 ISRAEL
16.5.5 EGYPT
16.5.6 REST OF MIDDLE EAST AND AFRICA
17 GLOBAL HAEMATOLOGY MARKET, COMPANY PROFILE
17.1 ABBOTT
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 GEOGRAPHIC PRESENCE
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENTS
17.2 BIO-RAD LABORATORIES, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 GEOGRAPHIC PRESENCE
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 BECKMAN COULTER, INC. ( DANAHER)
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 GEOGRAPHIC PRESENCE
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 THERMO FISHER SCIENTIFIC INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 GEOGRAPHIC PRESENCE
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 SIEMENS HEALTHCARE PRIVATE LIMITED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 GEOGRAPHIC PRESENCE
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENTS
17.6 ERBA MANNHEIM
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 GEOGRAPHIC PRESENCE
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENTS
17.7 HORIBA GROUP
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 GEOGRAPHIC PRESENCE
17.7.4 PRODUCT PORTFOLIO
17.7.5 RECENT DEVELOPMENTS
17.8 NIHON KOHDEN CORPORATION
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 GEOGRAPHIC PRESENCE
17.8.4 PRODUCT PORTFOLIO
17.8.5 RECENT DEVELOPMENTS
17.9 SYSMEX CORPORATION (TOA CORPORATION)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 GEOGRAPHIC PRESENCE
17.9.4 PRODUCT PORTFOLIO
17.9.5 RECENT DEVELOPMENTS
17.1 BOULE
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 GEOGRAPHIC PRESENCE
17.10.4 PRODUCT PORTFOLIO
17.10.5 RECENT DEVELOPMENTS
17.11 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 GEOGRAPHIC PRESENCE
17.11.4 PRODUCT PORTFOLIO
17.11.5 RECENT DEVELOPMENTS
17.12 DIATRON
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 GEOGRAPHIC PRESENCE
17.12.4 PRODUCT PORTFOLIO
17.12.5 RECENT DEVELOPMENTS
17.13 DREW SCIENTIFIC
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 GEOGRAPHIC PRESENCE
17.13.4 PRODUCT PORTFOLIO
17.13.5 RECENT DEVELOPMENTS
17.14 EKF DIAGNOSTICS HOLDINGS PLC
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 GEOGRAPHIC PRESENCE
17.14.4 PRODUCT PORTFOLIO
17.14.5 RECENT DEVELOPMENTS
17.15 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 GEOGRAPHIC PRESENCE
17.15.4 PRODUCT PORTFOLIO
17.15.5 RECENT DEVELOPMENTS
17.16 SPINREACT
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 GEOGRAPHIC PRESENCE
17.16.4 PRODUCT PORTFOLIO
17.16.5 RECENT DEVELOPMENTS
17.17 VANGUARD DIAGNOSTICS
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 GEOGRAPHIC PRESENCE
17.17.4 PRODUCT PORTFOLIO
17.17.5 RECENT DEVELOPMENTS
17.18 AGD BIOMEDICALS PVT. LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 GEOGRAPHIC PRESENCE
17.18.4 PRODUCT PORTFOLIO
17.18.5 RECENT DEVELOPMENTS
17.19 NORMA INSTRUMENTS
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 GEOGRAPHIC PRESENCE
17.19.4 PRODUCT PORTFOLIO
17.19.5 RECENT DEVELOPMENTS
17.2 TERUMO BCT, INC. (TERUMO CORPORATION)
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 GEOGRAPHIC PRESENCE
17.20.4 PRODUCT PORTFOLIO
17.20.5 RECENT DEVELOPMENTS
17.21 ARKRAY, INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 GEOGRAPHIC PRESENCE
17.21.4 PRODUCT PORTFOLIO
17.21.5 RECENT DEVELOPMENTS
17.22 TRIVITRON HEALTHCARE
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 GEOGRAPHIC PRESENCE
17.22.4 PRODUCT PORTFOLIO
17.22.5 RECENT DEVELOPMENTS
17.23 BIOGENIX INC. PVT. LTD.
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 GEOGRAPHIC PRESENCE
17.23.4 PRODUCT PORTFOLIO
17.23.5 RECENT DEVELOPMENTS
17.24 HESKA CORPORATION ( ANTECH DIAGNOSTICS, INC.)
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 GEOGRAPHIC PRESENCE
17.24.4 PRODUCT PORTFOLIO
17.24.5 RECENT DEVELOPMENTS
17.25 ORPHÉE
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 GEOGRAPHIC PRESENCE
17.25.4 PRODUCT PORTFOLIO
17.25.5 RECENT DEVELOPMENTS
17.26 CHENGDU SEAMATY TECHNOLOGY CO., LTD.
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 GEOGRAPHIC PRESENCE
17.26.4 PRODUCT PORTFOLIO
17.26.5 RECENT DEVELOPMENTS
17.27 BIOSURFIT SA, SPINIT
17.27.1 COMPANY SNAPSHOT
17.27.2 REVENUE ANALYSIS
17.27.3 GEOGRAPHIC PRESENCE
17.27.4 PRODUCT PORTFOLIO
17.27.5 RECENT DEVELOPMENTS
17.28 THARMAC GMBH
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 GEOGRAPHIC PRESENCE
17.28.4 PRODUCT PORTFOLIO
17.28.5 RECENT DEVELOPMENTS
17.29 BEHNK ELEKTRONIK GMBH & CO.
17.29.1 COMPANY SNAPSHOT
17.29.2 REVENUE ANALYSIS
17.29.3 GEOGRAPHIC PRESENCE
17.29.4 PRODUCT PORTFOLIO
17.29.5 RECENT DEVELOPMENTS
17.3 JIANGSU ACCURACY BIOTECHNOLOGY CO., LTD.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 GEOGRAPHIC PRESENCE
17.30.4 PRODUCT PORTFOLIO
17.30.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
18 RELATED REPORTS
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.